Valeant Short Seller Picks Next Target

The video discusses the decline of Valiant's stock following Citron's report linking it to a specialty pharmacy. It then shifts focus to Transdigm, drawing parallels between the two companies' strategies of raising prices on niche products. Citron's report on Transdigm is met with skepticism by analysts, highlighting the company's financial vulnerabilities, including significant debt and the need for consistent earnings performance.

What is the main argument presented by Citron regarding Transdigm?

What financial challenges does Transdigm face as mentioned in the text?